Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Migration, Crosslink

📖

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

active

wiki page Created: 2026-04-02T07:19:02 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-therapeutics-neural-network-synchro

📖 Wiki Page

therapeutic1597 wordssynced 2026-04-02

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neural Network Dysfunction and Synchronization Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Metric</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Theta power</td>
<td>↑↑</td>
</tr>
<tr>
<td class="label">Alpha power</td>
<td>↓↓</td>
</tr>
<tr>
<td class="label">Beta power</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Gamma power</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Coherence</td>
<td>↓ Frontoparietal</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency rTMS</td>
<td>M1/DLPFC</td>
</tr>
<tr>
<td class="label">Low-frequency rTMS</td>
<td>M1</td>
</tr>
<tr>
<td class="label">Theta burst (TBS)</td>
<td>Various</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>DLPFC</td>
</tr>
<tr>
<td class="label">Oscillation</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Beta bands (13-35 Hz)</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Theta bands (4-8 Hz)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Gamma bands (30-100 Hz)</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Cross-frequency coupling</td>
<td>Abnormal</td>
</tr>
<tr>
<td class="label">NET Domain</td>
<td>S

...

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Neural Network Dysfunction and Synchronization Therapy for CBS/PSP</th>
</tr>
<tr>
<td class="label">Metric</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Theta power</td>
<td>↑↑</td>
</tr>
<tr>
<td class="label">Alpha power</td>
<td>↓↓</td>
</tr>
<tr>
<td class="label">Beta power</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Gamma power</td>
<td>↓</td>
</tr>
<tr>
<td class="label">Coherence</td>
<td>↓ Frontoparietal</td>
</tr>
<tr>
<td class="label">Protocol</td>
<td>Target</td>
</tr>
<tr>
<td class="label">High-frequency rTMS</td>
<td>M1/DLPFC</td>
</tr>
<tr>
<td class="label">Low-frequency rTMS</td>
<td>M1</td>
</tr>
<tr>
<td class="label">Theta burst (TBS)</td>
<td>Various</td>
</tr>
<tr>
<td class="label">iTBS</td>
<td>DLPFC</td>
</tr>
<tr>
<td class="label">Oscillation</td>
<td>Pathological</td>
</tr>
<tr>
<td class="label">Beta bands (13-35 Hz)</td>
<td>Elevated</td>
</tr>
<tr>
<td class="label">Theta bands (4-8 Hz)</td>
<td>Variable</td>
</tr>
<tr>
<td class="label">Gamma bands (30-100 Hz)</td>
<td>Reduced</td>
</tr>
<tr>
<td class="label">Cross-frequency coupling</td>
<td>Abnormal</td>
</tr>
<tr>
<td class="label">NET Domain</td>
<td>Score Range</td>
</tr>
<tr>
<td class="label">Executive</td>
<td>0-100</td>
</tr>
<tr>
<td class="label">Memory</td>
<td>0-100</td>
</tr>
<tr>
<td class="label">Attention</td>
<td>0-100</td>
</tr>
<tr>
<td class="label">Composite</td>
<td>0-100</td>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>TMS/DBS Interaction</td>
</tr>
<tr>
<td class="label">Anticonvulsants</td>
<td>May reduce rTMS efficacy</td>
</tr>
<tr>
<td class="label">Benzodiazepines</td>
<td>May enhance sedation</td>
</tr>
<tr>
<td class="label">Antidepressants</td>
<td>Generally safe</td>
</tr>
<tr>
<td class="label">Dopamine agonists</td>
<td>May interact with DBS</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>Intervention</td>
</tr>
<tr>
<td class="label">1</td>
<td>Pharmacological optimization</td>
</tr>
<tr>
<td class="label">2</td>
<td>rTMS (targeted)</td>
</tr>
<tr>
<td class="label">3</td>
<td>Gamma entrainment</td>
</tr>
<tr>
<td class="label">4</td>
<td>DBS (refractory cases)</td>
</tr>
</table>

Corticobasal Syndrome (CBS) and Progressive Supranuclear Palsy (PSP) are 4R-tauopathies characterized by progressive motor and cognitive decline. These disorders involve widespread disruption of brain networks, particularly those involving the basal ganglia, thalamus, and cortical circuits. This page reviews the network-level dysfunction in these conditions and discusses therapeutic approaches targeting network synchronization, including neuromodulation techniques and pharmacological interventions.

Brain Network Disruption in 4R-Tauopathies

Default Mode Network (DMN)

The Default Mode Network (DMN) is a constellation of brain regions active during rest and internally directed cognition. In CBS and PSP, DMN connectivity is markedly disrupted:

Posterior cingulate cortex (PCC): Reduced connectivity with prefrontal regions correlates with cognitive impairment
Medial prefrontal cortex (mPFC): Decreased functional connectivity reflects executive dysfunction
Precuneus: Hyperconnectivity in early stages, progressing to hypoconnectivity as disease advances

The DMN disruption in CBS/PSP differs from Alzheimer's disease patterns, with more prominent involvement of anterior rather than posterior regions[@gloor2020].

Salience Network (SN)

The Salience Network, comprising the anterior cingulate cortex (ACC), anterior insula, and subcortical structures (particularly the striatum and pallidum), is critical for detecting salient stimuli and guiding behavior:

Anterior insula: Hyperconnectivity reflects enhanced sensitivity to external stimuli
ACC: Decreased connectivity correlates with apathy and behavioral disinhibition
Striatal involvement: Pathological tau deposition disrupts the striatal hub of the salience network

In PSP, salience network disruption correlates with the severity of axial rigidity and postural instability[@daniel2019].

Central Executive Network (CEN)

The Central Executive Network supports working memory, problem-solving, and goal-directed behavior:

Dorsolateral prefrontal cortex (DLPFC): Significant hypoconnectivity in both CBS and PSP
Posterior parietal cortex (PPC): Reduced connectivity correlates with spatial dysfunction
Lateral temporal regions: Variable involvement depending on clinical phenotype

EEG/MEG Biomarkers of Network Synchronization

EEG Findings in CBS/PSP

Quantitative EEG reveals characteristic abnormalities in 4R-tauopathies:

Network Synchronization Metrics

Phase locking value (PLV) and phase lag index (PLI) quantify phase synchronization between brain regions:

Interhemispheric coherence: Reduced in CBS, particularly over frontal regions
Intrahemispheric connectivity: Impaired frontoparietal coupling in both conditions
Cross-frequency coupling: Beta-gamma coupling abnormalities correlate with cognitive decline

MEG Biomarkers

Magnetoencephalography provides superior spatial resolution for network analysis:

Resting-state networks: Reduced sigma-band (12-15 Hz) connectivity in the dorsal attention network
Event-related fields: Impaired gamma responses during cognitive tasks
Source connectivity: Abnormal delta-beta coupling in the salience network[@torii2022]

Gamma Entrainment (40Hz) and Microglial Effects

Mechanism of Gamma Entrainment

40Hz gamma entrainment is an emerging therapeutic approach that originated from Alzheimer's disease research but has potential applications in 4R-tauopathies:

Visual/sensory stimulation at 40Hz drives cortical gamma oscillations

Entrainment propagates to deeper brain regions through thalamocortical circuits

Network-wide gamma synchronization can be achieved with repeated sessions

Effects on Microglia

A landmark study demonstrated that 40Hz gamma entrainment modifies microglial morphology and function:

Reduced microglial activation in the visual cortex and surrounding regions
Changed morphology from amoeboid to surveillant phenotype
Decreased cytokine expression including IL-1β and TNF-α
Enhanced clearance of pathological proteins through improved phagocytosis

The microglial effects appear mediated by the TREM2-SYK signaling pathway, which is critical for microglial phagocytosis[@iaccarino2016].

Application to CBS/PSP

While directly studied primarily in AD models, gamma entrainment may benefit CBS/PSP patients through:

Network synchronization: Restoring gamma coherence in frontoparietal networks
Microglial modulation: Reducing neuroinflammation associated with tau pathology
Cognitive enhancement: Improving attention and working memory through gamma entrainment

Safety and Implementation

Contraindications: Seizure history, implanted electronic devices, photosensitive epilepsy
Protocols: 40Hz visual flicker, auditory click trains, or combined audiovisual entrainment
Session duration: 1-2 hours daily over multiple weeks
Emerging devices: Wearable gamma entrainment headsets for home use

TMS/rTMS Network Modulation

Repetitive TMS (rTMS)

rTMS uses magnetic fields to induce electrical currents in cortical regions, modulating network activity:

Clinical Evidence in CBS/PSP

Motor cortex stimulation: Some studies show modest improvement in rigidity and bradykinesia DLPFC stimulation: May improve executive function and working memory Parietal stimulation: Experimental approaches for spatial dysfunction

Evidence is limited compared to Parkinson's disease, but rTMS remains a promising therapeutic avenue[@lefaucheur2019].

Network Effects of rTMS

rTMS modulates brain networks through:

Direct cortical effects: Alters excitability at stimulation site

Propagation via thalamocortical circuits: Effects spread to connected regions

Network-level changes: Restores functional connectivity in disrupted networks

Neurotransmitter modulation: Affects dopamine, GABA, and glutamate systems

Safety Considerations

Common side effects: Headache, scalp discomfort (transient)
Rare complications: Seizure (minimized with proper protocols)
Contraindications: Metal implants, seizure disorders, certain medications

Deep Brain Stimulation Network Effects

STN vs GPi: Network Mechanisms

Both targets modulate basal ganglia-thalamocortical networks but through distinct mechanisms:

Subthalamic Nucleus (STN):

Hyperdirect pathway modulation
More extensive network effects
Greater cognitive risk

Globus Pallidus interna (GPi):

Direct output modulation
More focal effects
Better cognitive safety profile

For CBS/PSP, GPi is generally preferred due to the high cognitive risk in tauopathies[@moriarty2022][@odekerken2023].

Network-Level Effects of DBS

DBS normalizes pathological network oscillations:

Closed-Loop DBS

Emerging approaches use real-time network monitoring:

Adaptive DBS: Responds to pathological oscillations
Network-triggered stimulation: Initiates based on specific connectivity patterns
Personalized targeting: Based on individual network topology[@chen2019]

Pharmacological Restoration of Network Balance

Glutamate Modulation

Excessive glutamate contributes to network hyperexcitability:

AMPA receptor modulators: Reduce excitatory transmission
mGluR modulators: Group I mGluR antagonists may stabilize networks
NMDA antagonists: Caution needed due to cognitive side effects

GABA Enhancement

GABAergic deficits contribute to network dysfunction:

Benzodiazepines: Short-term use for acute network stabilization
GABA-B agonists: May improve network inhibition
Novel agents: Positive allosteric modulators with improved safety profiles

Balance Therapy

The goal is to restore glutamate/GABA balance:

Network stability index: Ratio of excitatory to inhibitory activity
Biomarker-guided dosing: EEG-guided treatment optimization
Combination approaches: GABA enhancement plus neuromodulation[@boasso2020]

NET Assessment

Network Examination Test (NET)

The NET is a clinical tool for assessing network function:

Executive function tasks: Word fluency, trail-making
Memory encoding: Verbal learning and recall
Attention paradigms: Continuous performance tests
Processing speed: Digit symbol substitution

Clinical Applications

Baseline assessment: Establish pre-treatment network function
Treatment monitoring: Track improvements with therapy
Prognostication: Network integrity predicts treatment response

Interpretation

Drug Interactions

Interactions with Neuromodulation

Network-Active Drug Combinations

Combining pharmacological and neuromodulation approaches requires consideration:

Timing: Drug administration before or after TMS sessions
Dosing: Lower doses may be effective with combined approaches
Monitoring: EEG biomarkers to optimize combination therapy

Contraindicated Combinations

Seizure threshold-lowering drugs + high-frequency rTMS
Anticoagulants + invasive neuromodulation procedures
Certain psychiatric medications + specific DBS targets

Clinical Recommendations

Assessment Protocol

Baseline EEG/MEG: Characterize network dysfunction

NET evaluation: Establish cognitive profile

Imaging: Structural MRI for target planning

Trial stimulation: Test responsiveness before implantation

Therapeutic Hierarchy

Monitoring and Optimization

Regular EEG assessment: Track network changes
NET follow-up: Monitor cognitive function
Parameter adjustment: Optimize stimulation settings
Combination therapy: Integrate multiple approaches

Future Directions

Emerging Technologies

Closed-loop DBS: Real-time network-responsive stimulation
Temporal interference: Non-invasive deep brain stimulation
Personalized gamma protocols: Individualized frequency selection
Network avatars: Computational models for treatment optimization

Research Priorities

Biomarker development: Network-based predictors of treatment response
Mechanism studies: Understanding tau-mediated network dysfunction
Clinical trials: Large-scale studies of network-targeted interventions
Combination protocols: Optimizing multi-modal treatment approaches

References

[Gloor P et al., Default mode network abnormalities in corticobasal syndrome (2020)](https://pubmed.ncbi.nlm.nih.gov/32826348/)

[Daniel SE et al., Salience network disruption in progressive supranuclear palsy (2019)](https://pubmed.ncbi.nlm.nih.gov/31495321/)

[Torii T et al., EEG biomarkers of network synchronization in atypical parkinsonism (2022)](https://pubmed.ncbi.nlm.nih.gov/35645612/)

[Iaccarino HF et al., Gamma frequency entrainment attenuates amyloid load and modifies microglia (2016)](https://pubmed.ncbi.nlm.nih.gov/27929004/)

[Lefaucheur JP et al., Evidence-based guidelines on therapeutic use of transcranial magnetic stimulation (2019)](https://pubmed.ncbi.nlm.nih.gov/31346091/)

[Moriarty H et al., GPi deep brain stimulation for corticobasal syndrome (2022)](https://pubmed.ncbi.nlm.nih.gov/35248912/)

[Odekerken VJJ et al., GPi-DBS for progressive supranuclear palsy (2023)](https://pubmed.ncbi.nlm.nih.gov/36894218/)

[Chen R et al., Network-targeted stimulation in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31784765/)

[Lees AJ et al., Network dysfunction and gait in atypical parkinsonism (2019)](https://pubmed.ncbi.nlm.nih.gov/31755382/)

[Boasso E et al., Glutamate/GABA balance in tauopathy networks (2020)](https://pubmed.ncbi.nlm.nih.gov/32045789/)

📖 View canonical wiki page →

Related Entities

therapeutics-neural-network-synchronization-cbs-psp

▸Metadataorigin_type: v1_polymorphic_backfill

slug	therapeutics-neural-network-synchronization-cbs-psp
kg_node_id	None
entity_type	therapeutic
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-683933f57eae
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'therapeutics-neural-network-synchronization-cbs-psp'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

361

Outgoing

362

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Overview

Neural Network Dysfunction and Synchronization Therapy for CBS/PSP

Overview

Brain Network Disruption in 4R-Tauopathies

Default Mode Network (DMN)

Salience Network (SN)

Central Executive Network (CEN)

EEG/MEG Biomarkers of Network Synchronization

EEG Findings in CBS/PSP

Network Synchronization Metrics

MEG Biomarkers

Gamma Entrainment (40Hz) and Microglial Effects

Mechanism of Gamma Entrainment

Effects on Microglia

Application to CBS/PSP

Safety and Implementation

TMS/rTMS Network Modulation

Repetitive TMS (rTMS)

Clinical Evidence in CBS/PSP

Network Effects of rTMS

Safety Considerations

Deep Brain Stimulation Network Effects

STN vs GPi: Network Mechanisms

Network-Level Effects of DBS

Closed-Loop DBS

Pharmacological Restoration of Network Balance

Glutamate Modulation

GABA Enhancement

Balance Therapy

NET Assessment

Network Examination Test (NET)

Clinical Applications

Interpretation

Drug Interactions

Interactions with Neuromodulation

Network-Active Drug Combinations

Contraindicated Combinations

Clinical Recommendations

Assessment Protocol

Therapeutic Hierarchy

Monitoring and Optimization

Future Directions

Emerging Technologies

Research Priorities

References

💬 Discussion